Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
July 26 2022 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced plans to report second quarter
financial results on Tuesday, August 9, 2022, before market open.
The company will not be hosting a teleconference in conjunction
with its financial results press release.
About Rubius
Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical
company developing a new class of medicines called Red Cell
Therapeutics™. The Company’s proprietary RED PLATFORM® was designed
to biologically engineer and culture Red Cell Therapeutics™ that
are selective, potent and off-the-shelf allogeneic cellular
therapies for the potential treatment of several diseases across
multiple therapeutic areas. Rubius’ initial focus is to advance
RCT™ product candidates for the treatment of cancer and autoimmune
diseases by leveraging two distinct therapeutic modalities — potent
cell-cell interaction and tolerance induction.
Rubius Therapeutics was recently named among the 2021 Top
Places to Work in Massachusetts by the Boston Globe, and its
manufacturing site was recently named 2022 Best Places to
Work in Rhode Island by Providence Business News. For more
information, visit www.rubiustx.com, follow us on Twitter or
LinkedIn or like us on Facebook.
Contacts:InvestorsLori Murray,
Chief Corporate Affairs Officer lori.murray@rubiustx.com
MediaMarissa Hanify, Director, Corporate
Communications marissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Aug 2023 to Aug 2024